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Background: To distinguish between malignant and benign lesions of the thyroid gland histological
demonstration is often required since the fine-needle aspiration biopsy method applied pre-operatively has some
limitations. In an attempt to improve diagnostic accuracy, markers using immunocytochemistry and
immunohistochemistry techniques have been studied, mainly cytokeratin-19 (CK-19), galectin-3 (Gal-3) and Hector
Battifora mesothelial-1 (HBME-1). However, current results remain controversial. The aim of the present article was
to establish the diagnostic accuracy of CK-19, Gal-3 and HBME-1 markers, as well as their associations, in the
differentiation of malignant and benign thyroid lesions.
Methods: A systematic review of published articles on MEDLINE and The Cochrane Library was performed. After
establishing inclusion and exclusion criteria, 66 articles were selected. The technique of meta-analysis of diagnostic
accuracy was employed and global values of sensitivity, specificity, area under the summary ROC curve, and
diagnostic odds ratio (dOR) were calculated.
Results: For the immunohistochemistry technique, the positivity of CK-19 for the diagnosis of malignant thyroid
lesions demonstrated global sensitivity of 81% and specificity of 73%; for Gal-3, sensitivity of 82% and specificity of
81%; and for HBME-1, sensitivity of 77% and specificity of 83%. The association of the three markers determined
sensitivity of 85%, specificity of 97%, and diagnostic odds ratio of 95.1. Similar results were also found for the
immunocytochemistry assay.
Conclusion: This meta-analysis demonstrated that the three immunomarkers studied are accurate in pre- and
postoperative diagnosis of benign and malignant thyroid lesions. Nevertheless, the search for other molecular
markers must continue in order to enhance this diagnostic accuracy since the results found still show a persistency
of false-negative and false-positive tests.
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Figure 1 Flowchart of article selection.
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Thyroid gland carcinoma is a very prevalent neoplasia
worldwide. A survey sponsored by the World Health
Organization (WHO) in 2010 revealed that there are
around 44,670 new cases and 1,690 deaths caused by
this disease every year [1].
The majority of malignant lesions of the thyroid, such
as papillary carcinoma, medullary carcinoma and undif-
ferentiated histological types, can be diagnosed by cyto-
logical criteria using samples obtained by fine-needle
aspiration biopsy (FNAB) guided by ultrasonography [2].
Likewise, the diagnosis of benign lesions, such as hyper-
plastic nodules, colloid nodules and auto-immune dis-
eases like thyroiditis, can be cytologically established [3].
However, to distinguish between malignant and benign
lesions histological demonstration is often required for a
precise diagnosis. Therefore, they are cytologicallyTable 1 Number of studies, patients and their distributions in
technique
IHC ANALYSIS Studies Patients
CK-19[10,14-33] 21 3603
GAL-3[10,14-17,19,21,25-56] 39 5168
HBME-1[10,14-19,21,24-27,29,30,41,51,57-61] 21 3900
CK-19 +HBME-1[14,17] 2 157
GAL-3 + CK-19[14,17] 2 164
GAL-3 +HBME-1[14,17,46,51] 4 293
GAL-3 +HBME-1 + CK-19[14,17,29] 3 231
LEGEND: TP (true-positive), FP (false-positive), FN (false-negative) and TN (true-negagrouped as undetermined tumors or suspected follicular
neoplasia [4-7] and patients often undergo a diagnostic
surgical procedure (thyroidectomy) even though the
general carcinoma rate of this condition is very low [8].
Thus, the immunohistochemistry method plays a com-
plementary role in the attempt to clarify this dilemma
[9].
Many studies employ immunohistochemistry techni-
ques as an attempt to search for markers involved in the
genesis or specific characteristics of follicular patterned
tumors. Among the immunocytochemistry (ICC) or
immunohistochemistry (IHC) markers most employed
to distinguish between benign and malignant lesions of
the thyroid are: cytokeratin-19 (CK-19: a keratin mem-
ber family responsible for the structural integrity of epi-
thelial cells), galectin-3 (Gal-3: involved in the process of
cell migration, adherence and apoptosis) and Hectorcluded in each analysis by the immunohistochemistry
TP FP FN TN
1697 (47.1%) 433 (12.0%) 314 (8.7%) 1159 (32.2%)
2270 (43.9%) 528 (10.2%) 408 (7.9%) 1962 (38.0%)
1501 (38.5%) 324 (8.3%) 436 (11.2%) 1639 (42.0%)
84 (53.5%) 2 (1.3%) 14 (8.9%) 57 (36.3%)
90 (54.9%) 6 (3.7%) 9 (5.5%) 59 (36.0%)
119 (40.6%) 15 (5.1%) 40 (13.7%) 119 (40.6%)
121 (52.4%) 3 (1.3%) 22 (9.5%) 85 (36.8%)
tive).
Table 2 Sensitivity and specificity of each immunohistochemistry marker or association
IHC ANALYSIS Sensitivity (95% CI) Q P Specificity (95% CI) Q P
CK-19[10,14-33] 0.81 (0.79-0.83) 192.02 <0.00001 0.73 (0.70-0.75) 254.49 <0.00001
GAL-3[10,14-17,19,21,25-56] 0.82 (0.81-0.84) 341.95 <0.00001 0.81 (0.79-0.82) 512.70 <0.00001
HBME-1[10,14-19,21,24-27,29,30,41,51,57-61] 0.77 (0.76-0.79) 298.64 <0.00001 0.83 (0.82-0.85) 444.58 <0.00001
CK-19 +HBME-1[14,17] 0.86 (0.77-0.92) 0.41 0.5245 0.97 (0.89-1.00) 7.46 0.0063
GAL-3 + CK-19[14,17] 0.91 (0.83-0.96) 0.01 0.9383 0.91 (0.81-0.97) 5.31 0.0212
GAL-3 +HBME-1[14,17,46,51] 0.75 (0.67-0.81) 57.91 <0.00001 0.89 (0.82-0.94) 7.46 0.0587
GAL-3 +HBME-1 + CK-19[14,17,29] 0.85 (0.78-0.90) 0.25 0.8826 0.97 (0.90-0.99) 7.33 0.0256
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brane antigen that exists in the microvilli of the meso-
thelioma cells and also in follicular thyroid tumor cells)
or their associations [10]. However, their results and
applications are still controversial since these molecules
have not proved to have specificity and – more critically,
to avoid an eventual diagnostic thyroidectomy – enough
sensitivity in the differentiation of follicular lesions be-
cause of persistent variable rates of, respectively, false-
positive and false-negative results [11].
In view of this, the objective of the present study was
to establish the diagnostic accuracy of CK-19, Gal-3 and
HBME-1 markers, and their associations, for the differ-
entiation between benign and malignant thyroid lesions.Material and methods
Systematic review
A search for articles published exclusively in the English
language between January 2001 and December 2011 was
carried out in the electronic databases MEDLINE and
The Cochrane Library.
A wide strategy was employed in the search in order
to avoid publication bias, and the following describers
were used: ((ck-19 and thyroid) OR (galectin-3 and thy-
roid) OR (hbme-1 and thyroid)). Reference lists of previ-
ously obtained articles were also analyzed so that other
relevant studies could be identified for inclusion in the
present study.Table 3 Positive likelihood ratio (Positive LR) and negative lik
immunohistochemistry marker and association
IHC ANALYSIS Positive LR (95% CI)
CK-19[10,14-33] 2.87 (2.10-3.92) 2
GAL-3[10,14-17,19,21,25-56] 4.24 (3.08-5.82) 6
HBME-1[10,14-19,21,24-27,29,30,41,51,57-61] 6.93 (4.42-10.88) 3
CK-19 +HBME-1[14,17] 16.71 (0.38-742.57)
GAL-3 + CK-19[14,17] 8.49 (1.04-69.17)
GAL-3 +HBME-1[14,17,46,51] 4.92 (1.70-14.27) 1
GAL-3 +HBME-1 + CK-19[14,17,29] 17.19 (3.36-87.96)The exclusion criteria adopted for both the study as a
whole and for cases individually selected were as follows:
inability to obtain individual data, review articles, case
reports, use of the same sample, absence of case or con-
trol groups (as control group was considered any diag-
nosis of benign thyroid lesions, such as: goiter, follicular
adenoma, thyroiditis, hyperplasic nodules or normal thy-
roid samples), fewer than 12 patients in each group
(both case and control), individuals under 18 years, use
of any organ other than thyroid, use of any marker other
than CK-19, Gal-3 or HBME-1, inclusion of another
histological malignant type other than the well-
differentiated thyroid carcinoma, use of techniques other
than immunocytochemistry or immunohistochemistry,
use of specimens other than human, use of specimens
other than those obtained exclusively from the thyroid
gland (for example, blood and derivatives).
The data from the studies was independently col-
lected by two researchers, who employed a standardized
form. The following information was extracted: refer-
ence, number of patients in the case and control
groups, technique employed (immunocytochemistry or
immunohistochemistry), histological types of neoplasias
studied and results (stratified into four groups: true-
positive; false-positive; false-negative; and true-negative).
Differences in the data extracted were resolved by
group consensus.
Initially, 265 abstracts were selected and, after applying
the established criteria above, 66 articles were includedelihood ratio (Negative LR) of each
Q P Negative LR (95% CI) Q P
62.28 <0.00001 0.25 (0.18-0.35) 131.17 <0.00001
05.28 <0.00001 0.21 (0.15-0.30) 508.27 <0.00001
55.63 <0.00001 0.22 (0.16-0.30) 234.36 <0.00001
6.35 0.0118 0.16 (0.10-0.25) 0.11 0.7385
6.83 0.0089 0.10 (0.05-0.19) 0.15 0.6943
3.48 0.0037 0.23 (0.03-1.70) 107.69 <0.00001
3.69 0.1577 0.17 (0.11-0.24) 0.10 0.9508
Table 4 Diagnostic odds ratio (dOR) calculated for each immunohistochemistry marker or combination
IHC ANALYSIS dOR (95% CI) Q P
CK-19[10,14-33] 14.73 (8.20-26.45) 110.05 <0.00001
GAL-3[10,14-17,19,21,25-56] 23.41 (14.02-39.07) 252.72 <0.00001
HBME-1[10,14-19,21,24-27,29,30,41,51,57-61] 40.97 (21.42-78.37) 140.82 <0.00001
CK-19 +HBME-1[14,17] 119.06 (6.81-2080.37) 2.62 0.1058
GAL-3 + CK-19[14,17] 86.54 (10.8-693.52) 2.89 0.8292
GAL-3 +HBME-1[14,17,46,51] 21.94 (2.88-167.49) 21.16 0.0001
GAL-3 +HBME-1 + CK-19[14,17,29] 95.06 (25.17-359.08) 2.23 0.3280
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in Figure 1.
Meta-analysis
The Meta-DiScW Program (Clinical BioStatistics Unit –
Hospital Ramón y Cajal, Madrid, Spain) was employed
in all the analyses [12]. The method applied was the
meta-analysis of diagnostic tests of independent studies
stratified according to the size of the sample in each
study, using Mantel-Haenszel’s method: a fixed effect
estimated from the size of each study calculated by the
inverse of its variance. The random effect of each study
was established by the DerSimonian-Lair method and
the presence of heterogeneity among the studies was
estimated by the Cochrans Q-Test and was considered
significant when P<0.1.
Values of sensitivity, specificity, positive and negative
likelihood ratios, as well as their confidence intervals
(95% CI), were calculated separately for each study and
also for the studies grouped according to the type of
marker or associations. Forest-plots of the most relevant
results were performed.Figure 2 Forest-plot graph with results for sensitivity, specificity, pos
expression of the positive combination of CK-19, Gal-3 and HBME-1 i
[14,17,29].The diagnostic odds ratio (dOR) was also calculated. It
is an additional measure that expresses the accuracy of
the test and represents how much greater the chance of
achieving exactitude is when the test is positive as
opposed to when the test is negative.
Complementarily, ROC (Receiver Operating Character-
istic) analysis was done and areas under the summary
ROC curves were calculated. This method is different
from conventional ROC analysis, which compares test
accuracy over different thresholds for positivity, because
in an SROC graph each data point comes from a differ-
ent study, but diagnostic thresholds should be similar
for each study so as not to influence the shape of the
curve [13].
Results
The analyses of diagnostic accuracy of markers CK-19,
Gal-3 and HBME-1, and their associations, in the differ-
entiation of well-differentiated carcinoma and benign
thyroid lesions, were evaluated separately by the immu-
nohistochemistry and immunocytochemistry techniques,
as described below.itive and negative likelihood ratio of immunohistochemistry
n the diagnosis of well-differentiated malignant thyroid lesions
Table 5 Number of studies, patients and their distributions included in each analysis, for the immunocytochemistry
technique
ICC ANALYSIS STUDIES PATIENTS TP FP FN TN
CK-19[31,62,63] 3 230 111 (48.3%) 19 (8.3%) 27 (11.7%) 73 (31.7%)
GAL-3[31,64-75] 14 1785 581 (33.9%) 103 (6.0%) 104 (6.0%) 927 (54.1%)
HBME-1[31,62,64,66,74,76,77] 7 3900 1501 (38.5%) 324 (8.3%) 436 (11.2%) 1639 (42.0%)
LEGEND: TP (true-positive), FP (false-positive), FN (false-negative) and TN (true-negative).
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The present meta-analysis included 49 articles and 5168
patients in the broader analysis, with variable rates of
true-positive and true-negative tests, and with a consid-
erable rate of false results (Table 1).
The values for sensitivity, specificity, and likelihood
ratios and their respective heterogeneity coefficients are
detailed in Table 2 and Table 3. It was noted that these
values are very discrepant and not so high when the
immunomarkers are analyzed alone. Nonetheless, the as-
sociation of markers can significantly increase the diag-
nostic rates but with an important loss of references.
Diagnostic odds ratio (dOR) was calculated directly
from sensitivity and specificity values (Table 4). This
measurement represents the overall diagnostic power of
each test (a high dOR implies that the test shows good
diagnostic accuracy in all patients) and, as seen, the test
with greatest diagnostic accuracy and least inconsistency
in the distinction between benign and malignant thyroid
lesions is the positivity of the three combined markers
(CK-19, Gal-3 and HBME-1). Thus, the forest-plot
charts that summarize the individual results of the arti-
cles selected for this analysis in a global rate (“diamond”
as pooling symbol) for sensitivity, specificity, positive
and negative likelihood ratios are represented in
Figure 2.
Immunocytochemistry technique
The same analysis was performed for the three markers
with the exclusive aim of making a preoperative diagno-
sis of thyroid lesions. However, the combination of mar-
kers suitable for the application of meta-analysis was not
identified in the literature and the results were only
based on the individual expression of each molecule.
This analysis included 17 articles with a special focus
on HBME-1 analysis with 3900 samples included. False-
negative and false-positive rates were significant, and
diagnostic results showed that Galectin-3 had lowTable 6 Sensitivity and specificity of each immunocytochemis
ICC ANALYSIS Sensitivity (95% CI) Q
CK-19[31,62,63] 0.80 (0.73-0.87) 63.04
GAL-3[31,64-75] 0.85 (0.83-0.88) 64.53
HBME-1[31,62,64,66,74,76,77] 0.83 (0.79-0.86) 15.30negative LR and high sensitivity, specificity and positive
LR with the highest diagnostic odds ratio, an analysis
with less heterogeneity; demonstrating that this marker
is the best at making a preoperative distinction between
benign and malignant thyroid lesions. The results are
described in Tables 5, 6, 7, and 8.
Exploring heterogeneity
The first factor of heterogeneity loss in the analyses
employing the immunohistochemistry technique was the
combination of markers, as previously shown. Therefore,
it became clear that none of these molecules, when stud-
ied independently, can reliably differentiate between be-
nign and well-differentiated malignant tumors of the
thyroid.
Therefore, in a search for other factors involved in the
determination of heterogeneity causes, the following
possible confounding variables were evaluated: inclusion
of oncocytic or Hürthle cells in the sample and/or the
criterion adopted to consider a marker as “positive”.
When both techniques (imunocytochemistry and
immunohistochemistry) are considered, the review of
the selected studies indicated that some authors actually
included oncocytic patterned tumors (or Hürthle cell
neoplasias) in their samples. Hürthle cells are character-
ized by their wide and granular cytoplasm and, besides,
most oncocytic lesions at cytology are shown to be be-
nign lesions upon histopathological examination
(Hürthle cell adenomas, hyperplastic nodules, thyroiditis
and Graves’ disease), the mere presence of these cells in
a cytological exam indicates a greater likelihood of ma-
lignancy (Bethesda IV), regardless of other criteria [78].
These factors make an exact etiological preoperative
diagnosis of these neoplasms even more difficult [79].
It was also observed that in some studies the immu-
nostaining was considered to be positive when at least
5% of the cells expressed the marker, whereas this mini-
mum percentage was considered by others to be 10%,try marker
P Specificity (95% CI) Q P
<0.00001 0.79 (0.70-0.87) 23.50 <0.00001
<0.00001 0.90 (0.88-0.92) 48.39 <0.00001
0.0180 0.79 (0.75-0.84) 48.62 <0.00001
Table 7 Ratios of positive likelihood (Positive LR) and of negative likelihood (Negative LR) of each
immunocytochemistry marker
ICC ANALYSIS Positive LR (95% CI) Q P Negative LR (95% CI) Q P
CK-19[31,62,63] (0.80-33.17) 28.16 <0.00001 0.26 (0.18-0.36) 1.48 0.4765
GAL-3[31,64-75] 7.73 (5.54-10.79) 40.40 0.0001 0.15 (0.09-0.22) 65.52 <0.00001
HBME-1[31,62,64,66,74,76,77] 6.71 (2.92-15.44) 52.38 <0.00001 0.20 (0.14-0.30) 15.62 0.0159
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weak, heterogeneous or sometimes even focal, it was
likewise, considered positive.
Thus, when the combination of markers was then ana-
lyzed (only for immunohistochemistry analysis), and
after removing Hürthle cells from the data and reclassi-
fying the cases with a percentage of immunostained cells
below 25%, weak or focal marking as “negative”, it was
possible to exclude the previously noted heterogeneity
from the groups (data not shown). SROC curves were
plotted at this time to thresholds of the different studies
to make them more similar and to better illustrate these
results (immunohistochemistry – Figure 3 and immuno-
cytochemistry – Figure 4). However, when these same
variables were excluded and a new analysis of CK-19,
Gal-3 and HBME-1 was undertaken separately, there
was always the presence of unequivocal heterogeneity
for the immunohistochemical technique. As the meta-
analysis was performed exclusively on published studies
and did not use the authors’ original data, in some
instances the criteria described above could not be ap-
plied with certainty; thus, these articles were excluded
from the analysis.Discussions
The preoperative diagnosis of thyroid lesions is not the
only challenge faced by pathologists. Very often, estab-
lishing the differential diagnosis between benignancy
and malignancy of a thyroid nodule, based only on the
histopathological exam, can be quite difficult.
One of the greatest research challenges involving well-
differentiated thyroid carcinoma is to develop a method
to enable the correct differential diagnosis between be-
nign and malignant lesions, trying to avoid a diagnostic
surgery. To really reach this objective a test would need
to have an especially high sensitivity rate,[11] but it has
not yet been achieved in the literature even when gen-
omic classifiers are employed [80]. Thus, the search forTable 8 Diagnostic odds ratio (dOR) calculated for each
immunocytochemistry marker
ICC ANALYSIS dOR (95% CI) Q p
CK-19[31,62,63] 30.31 (12.64-72.66) 0.46 0.7954
GAL-3[31,64-75] 64.18 (36.26-113.61) 31.98 0.0024
HBME-1[31,62,64,66,74,76,77] 42.28 (13.02-137.28) 34.44 <0.00001a “marker” that enhances this diagnostic capability is on-
going [81].
Cytokeratin-19 (CK-19) expression in thyroid nodules
is in general intense and diffuse in papillary carcinoma
and heterogeneous labeling in carcinoma and in follicu-
lar adenoma, with nil or low expression in other benign
lesions [30,82]. Galectins, especially galectin-3, are sug-
gested to play a role in the pathogenesis of well-
differentiated thyroid carcinoma, particularly in papil-
lary carcinoma[83] and, therefore, it is one of the mar-
kers most commonly used to assist in distinguishing
thyroid lesions. Hector Battifora mesothelial-1 (HBME-1)
has been demonstrated to be important as a thyroid
marker of follicular origin, with greater affinity to ma-
lignant lesions when compared to benign lesions[84].
Because of that, they are the three most used immuno-
markers in pathology practice and each of them had
different rates of false-negatives and false-positive
results and some authors advocate that a panel of the
three markers might be more helpful than the use of a
single immunomarker, improving the specificity, posi-
tive and negative predictive value and thus diagnostic
accuracy [85].Figure 3 SROC curve for positive immunohistochemistry
expression of the association of the three markers (CK-19,
Gal-3, HBME-1) in the diagnosis of well-differentiated
malignant thyroid lesions. Area under the SROC curve: 93.25%.
Figure 4 SROC curve for positive immunocytochemistry expression of CK-19, Gal-3 and HBME-1 in the diagnosis of well-differentiated
malignant lesions of the thyroid. Areas under the SROC curve: CK-19=86.32%; Gal-3=97.07%; HBME-1=94.12%.
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precisely quantify the accuracy of values of these three
important markers employed in clinical practice. Several
literature reviews have already been published but the
present study is the first to analyze cumulative data and
is worthy for this reason.
As demonstrated, the association of positivity for CK-
19, Gal-3 and HBME-1 in IHC assays and the preopera-
tive expression of galectin-3 in ICC samples proved to
be highly accurate tests in the distinction between be-
nign and well-differentiated thyroid carcinoma. This is
further noted when heterogeneity factors were disre-
garded; the SROC analysis showed a global accuracy of
more than 90% in this situation.
However, these results must be analyzed with great
care. Despite the fact that the accuracy rates are, in gen-
eral, high there is a considerable percentage of false-
results. When a diagnostic test could potentially produce
a false-negative result this is not a good reason to take a
watchful waiting approach, especially when a malignant
neoplasm is the object of the study, and many patients
are subjected to a theoretically unnecessary diagnostic
surgery, with associated morbidity and mortality rates.
Another important point of this study was the deter-
mination of heterogeneity variables involved in the ana-
lysis of tumors markers employed in thyroid nodule
diagnosis. Thus, the combination of markers, the exclu-
sion of Hürthle cells and the review of what must be
considered positive immunostaining were the main het-
erogeneity factors identified. Another possible hetero-
geneity factor that might be considered and that was not
possible to evaluate in this research has to do with the
technical methodology applied in the immunohisto-
chemical reactions like specimen fixation, monoclonal or
polyclonal antibodies, biotin-free detection method, etc.
These parameters should be standardized in future
works in order to achieve uniformity in the studies and
improvement in diagnostic accuracy of the immunocyto-
chemistry and immunohistochemistry methods.Nevertheless, this study has some limitations. The pre-
sent review might have been influenced by publication
bias since it was limited to articles in English and
included only published articles. However, the wide
search criteria applied and the rigorous exclusion criteria
have helped to ensure the inclusion of the most relevant
studies.
In summary, this meta-analysis demonstrated that the
three studied immunomarkers are accurate in making a
pre- and postoperative distinction between benign and
malignant thyroid lesions with accuracy of around 90%
for both immunocytochemistry and immunohistochemis-
try assays, despite avoiding variables responsible for het-
erogeneity in the analysis. Although, the search for other
molecular markers must continue in order to enhance
this diagnostic accuracy since the results found still show
persistency of false-negative and false-positive tests.
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